For this month’s issue of PME I spoke with Ipsen’s new chief executive David Meek about his company’s strategy for growth and – appropriately enough, as we sat down at the ESMO meeting in Copenhagen – his hopes for Ipsen’s new cancer drug Cabometyx.
We covered the strategic pillars Ipsen is counting on for success and looked at the strong progress the French firm is making in the US – where for the first year its operations there are its number one affiliate by revenue – and the changes to its primary care business model in China.
The magazine’s latest issue also puts behavioural change under the spotlight in a special section that covers areas such as translating the theory into practice, applying it to brand planning and the supporting function played by design.
Additionally, November’s PME has a report on a roundtable meeting convened last month to examine the impact of the millennial HCP. It saw an impressive line-up of participants investigate the positive changes millennials are bringing to healthcare and look at how millennial attitudes aren’t restricted to ‘generation now’.